Make Informed Investment Decisions with Affordable Access to Experts
Fridays with Adam Feuerstein #1Ticker(s): JAZZ, SAGE, CELG, GLPG, VRTX
Name: Adam Feuerstein
Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. A veteran journalist, Adam was most recently Senior Columnist at TheStreet, where he wrote about biotech and drug stocks. Adam lives near Boston with his wife, two kids and Bo, an insanely cute boxer/mutt.
Join now and add your questions for Adam F.!Added By: joe_mccann
what are your thoughts about GBT & DBVT?Added By: aklapholz
Can you gauge the impact on VRTX Cf franchise if GLPG competing product was shown to be efficacious?Added By: alexander poulos
Always a bad sign when a drug gets returned from a partner but what do you think about ARDX data? Met end-points. Then there is the IBS-C indication coming then later hyperkalemia drug(s).Added By: bin2gray
Do you think there's any more appetite in the market for more kinase inhibitor focused companies? Thoughts on BPMC? LOXO? Ignyta?
Do you think there's still a future for CAR-T companies? KITE, JUNO, UNUM?Added By: userd16bd1d0
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.